Stock

Down we go.....

 

All options on the table for Alcon...let's see who wants to buy this destroyed unit. Novartis raided the pharma products, left with contacts and surgical equip with declining sales and no profitability...lets see

 

plunge will continue

 

It looks like as if the share buyback has some impact.

 

artificial at best...

 

All you brilliant market prognosticators have shown up over the last 10 -15 years with the dire warnings of imminent collapse and bankruptcy. In the meantime, the smart money has been buying shares and reaping the benefits of a top global company with massive cash reserves. Doesn't matter what you think of NVS and how they do business/treat their employees - the financial world runs its own race with its own rules.

 

You are very smart, but the share price of Novartis is roughly at the same level as 10 years ago.

Your remark about the "massive cash reserves" is most likely just a typo. Because the announced share buyback will be financed by debt.

This actually is really cool and will help all of us to feel somewhat richer.

Or maybe somebody who is just much smarter than we all together is brilliantly preparing his own exit.

 

Cowen Downgrades Novartis, Strengths 'Now Balance Its Risks'

Jayson Derrick ,
April 05, 2017 12:36pm

Steve Scala of Cowen downgraded shares of Novartis AG (ADR) NVS 1.34% from Outperform to Market Perform with a price target lowered to $77 from $87 as the company's strengths "now balance its risks."

According to Scala's estimates, Novartis' earnings per share growth from 2016 through 2022 is expected to be 6 percent, which falls short of the industry average of 9 percent. Moreover, the analyst doesn't see any room for EPS revisions as the company's pharmaceutical and Alcon segments will require incremental spending moving forward.

While Alcon's recovery is ongoing the analyst argued there is no timing when Novartis can demonstrate any tangible results in the top and bottom line. Similarly, Novartis' Entresto continues to build at a slow pace and faces obstacles in the near term such as adoption.

No Major Events In 2017
In fact, Scala sees Novartis' 2017 EPS to fall by 1 percent in 2017 to $4.70 and even the analyst's convictions in his 2022 earnings per share estimate of $6.85 is "not high."

Scala argued that among Novartis' 20 upcoming many events this year, few will be "major" other than RTH258 Phase 3 data in we AMD in the bottom half of 2017 and a "Meet Management" event scheduled for June.

Bottom line, the company's lack of new pipeline opportunists and below industry average growth prompted the analyst to become less positive on the stock's outlook.

 

Well, even that he's not able to achieve our dear JJ
73$ Let's send more people to low cost locations, it seems to work pretty well...

 

WTF just happened? Making progress the today going right in the toilet!

 

Yep....keep the 'sky is falling' mentality - the bulls love seeing the shorts get squeezed.

 

Ilaris a $6Bn blockbuster?
NVS back on way to 100 buck chuck.

 

Going in the toilet again......

 

To steal your dinner ?

 

Guess the investors didn't like what they heard.....

 

Headed back under 80 again.

 

A dog w/ management leadership fleas.

 

Outcome of Alcon strategy review was as expected. Why was it even touted one year ago? It is obvious that NVS needs to deliver on the turnaround first before pursuing any option.

The debt financed share buyback seems to be the only thing that is executed well these days.

 

Not so fast!
But, if it stays below 80 for a week or so, then you can bet 65 is coming sooner than 85.

 

Another way of looking at the situation: NVS bets against NewRepublicOfAlcon through 2019.